Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE A series of studies has revealed that mutations of KRAS are involved in gastric carcinogenesis. 19639197

2009

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE These results provide new insights into mutant KRAS function and its role in carcinogenesis. 23580570

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE These results suggest that (1) the K-ras and p53 gene alterations would have no special roles in terms of the lung carcinogenesis in young adults; (2) a positive relationship between smoking and p53 gene alteration would exist in young adults with lung cancer, and (3) K-ras gene alteration would become a prognostic factor in lung cancer. 7715905

1995

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Rb and K-ras gene abnormalities may occur independently of each other during endometrial carcinogenesis in humans. 11179836

2001

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE Several lines of evidence indicate that mutational activation of KRAS is an early event in the carcinogenesis of non-small cell lung cancer (NSCLC). 23022742

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. 21636548

2011

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE The presence of these mutations did not vary according to the degree of dysplasia (GNAS: invasive 61%, high-grade 59%, low-grade 53%; KRAS: invasive 71%, high-grade 62%, low-grade 74%), suggesting that mutations in these genes occur early in IPMN carcinogenesis. 25840541

2015

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE We report here, for the first time, that caveolin-1 is a target of the K-RAS oncogene in colon carcinogenesis. 23280667

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Diet-induced unresolved ER stress hinders KRAS-driven lung tumorigenesis. 25533479

2015

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Taken together, our findings indicate that miR-193b-mediated deregulation of the KRAS axis is involved in pancreatic carcinogenesis, and suggest that miR-193b could be a potentially effective target for PDAC therapy. 25905463

2015

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE These results suggest that carcinogenesis in the biliary tract epithelium in APBDU is accompanied by multistep genetic mutational events; K-ras gene mutation occurs early in epithelial hyperplasia or metaplasia, whereas inactivation of the DPC-4 gene accumulates late in the progression of biliary tract adenocarcinoma. 12720172

2003

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE Our findings suggest that mutational activation of the K-ras gene is a common event in colon carcinogenesis and that HPV infection may represent an important factor in the development of the premalignant lesions leading to the neoplastic phenotype. 16672071

2006

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Mutations in KRAS and TP53 are common in colorectal carcinogenesis and are associated with resistance to therapy. 23456389

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Here we explore how nutrients and caloric intake may influence the KRAS-driven ductal carcinogenesis through mediators of metabolic stress, including autophagy in presence of TP53, advanced glycation end products (AGE) and the receptors (RAGE) and ligands (HMGB1), as well as glutamine pathways, among others. 24704294

2015

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Targeting cytokine networks in KRAS-driven tumorigenesis. 24928447

2014

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Our data highlight a pivotal role of the cooperative interaction between obesity-ensuing HFD and oncogenic KRAS in driving the heightened aerobic glycolysis during pancreatic tumorigenesis and suggest that in addition to directly targeting KRAS and aerobic glycolysis pathway, strategies to target the upstream of KRAS hyperactivation may bear important therapeutic value. 30819189

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE The high frequency of transitions among K-RAS mutation suggests that G/T mismatches play an important role in the oncogenesis of colorectal adenocarcinoma, implying that alkylating carcinogens may be involved in the colorectal carcinogenesis. 15771905

2005

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Our results showed that the PM of K-ras gene at codon 12 was a fairly common event in genetic abnormality and suggested it would have some role in the progression of carcinogenesis in endometrial carcinoma. 8428691

1993

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Mutations in KRAS are initiating events in pancreatic carcinogenesis supported by genetically engineered mouse models of the disease. 29079305

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Although epidermal growth factor receptor (EGFR)/KRAS mutation-driven lung tumorigenesis is well understood, the mechanism of EGFR/KRAS-independent signal activation remains elusive. 27593936

2017

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Histopathological and oncological examinations indicated that the lesions were involved in the development and progression of carcinogenesis because a point mutation of the K- ras gene and overexpression of p53 protein were detected. 12444445

2002

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Oncogenic mutations in KRAS contribute to the development of pancreatic ductal adenocarcinoma, but are not sufficient to initiate carcinogenesis. 25623042

2015

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Given that K-Ras plays a crucial role in mediating oncogenesis in the pancreas, we treated transformed pancreatic cells of both BxPC-3 and MiaPaCa-2 with 2-D08, a small ubiquitin-like modifier (SUMO) E2 inhibitor. 30228186

2018

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Despite being studied for more than 30 years, new information continues to develop regarding KRAS and its role in colon carcinogenesis. 23636143

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE For more than 20 years it has been recognized that constitutively active signaling downstream of KRAS is a fundamental driver of lung tumorigenesis. 26714748

2016